Scholar Rock Appoints Beth Shafer, Ph.D., to Chief Business Officer
Scholar Rock (NASDAQ: SRRK) has appointed Beth Shafer, Ph.D., as Chief Business Officer, a newly created role. With over 20 years of biopharmaceutical industry experience, Dr. Shafer will drive the company's long-term corporate and business development strategy. She joins from Voyager Therapeutics, where she served as Chief Business Officer. Previously, she held leadership positions at Takeda, Novartis, and Roche.
Scholar Rock is a late-stage biopharmaceutical company focusing on innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other diseases where protein growth factors play a key role. The appointment comes at a transformative time for the company as it aims to build an integrated biopharmaceutical company and advance its pipeline of therapies in high-value areas.
Scholar Rock (NASDAQ: SRRK) ha nominato Beth Shafer, Ph.D., come Chief Business Officer, un ruolo di nuova creazione. Con oltre 20 anni di esperienza nell'industria biofarmaceutica, la Dr.ssa Shafer guiderà la strategia di sviluppo aziendale e corporate a lungo termine della compagnia. Proviene da Voyager Therapeutics, dove ha ricoperto il ruolo di Chief Business Officer. In precedenza, ha ricoperto posizioni di leadership presso Takeda, Novartis e Roche.
Scholar Rock è un'azienda biofarmaceutica in fase avanzata che si concentra su trattamenti innovativi per l'atrofia muscolare spinale (SMA), i disturbi cardiometabolici e altre malattie in cui i fattori di crescita proteica giocano un ruolo chiave. La nomina avviene in un momento di trasformazione per l'azienda, che mira a costruire un'azienda biofarmaceutica integrata e a far avanzare il suo portafoglio di terapie in aree ad alto valore.
Scholar Rock (NASDAQ: SRRK) ha designado a Beth Shafer, Ph.D., como Directora de Negocios, un rol recién creado. Con más de 20 años de experiencia en la industria biofarmacéutica, la Dra. Shafer impulsará la estrategia de desarrollo corporativo y empresarial a largo plazo de la compañía. Se une desde Voyager Therapeutics, donde se desempeñó como Directora de Negocios. Anteriormente, ocupó puestos de liderazgo en Takeda, Novartis y Roche.
Scholar Rock es una empresa biofarmacéutica en etapa avanzada que se centra en tratamientos innovadores para la atrofia muscular espinal (AME), trastornos cardiometabólicos y otras enfermedades donde los factores de crecimiento proteico desempeñan un papel clave. La designación se produce en un momento transformador para la empresa, que busca construir una compañía biofarmacéutica integrada y avanzar en su cartera de terapias en áreas de alto valor.
Scholar Rock (NASDAQ: SRRK)는 Beth Shafer, Ph.D.를 최고 사업 책임자로 임명했습니다. 이는 새로 생성된 역할입니다. 20년 이상의 생물 제약 산업 경력을 가진 Shafer 박사는 회사의 장기 기업 및 사업 개발 전략을 추진할 것입니다. 그녀는 Voyager Therapeutics에서 최고 사업 책임자로 재직하였으며, 이전에는 Takeda, Novartis 및 Roche에서 리더십 직책을 맡았습니다.
Scholar Rock은 척수 근위축증(SMA), 심혈관 대사 장애 및 단백질 성장 인자가 중요한 역할을 하는 기타 질병을 위한 혁신적인 치료법에 집중하는 후기 단계의 생물 제약 회사입니다. 이번 임명은 회사가 통합 생물 제약 회사를 구축하고 고부가 가치 영역에서 치료제 파이프라인을 추진하고자 하는 혁신적인 시기에 이루어졌습니다.
Scholar Rock (NASDAQ: SRRK) a nommé Beth Shafer, Ph.D., au poste de Chief Business Officer, un rôle nouvellement créé. Avec plus de 20 ans d'expérience dans l'industrie biopharmaceutique, le Dr Shafer conduira la stratégie de développement corporate et commercial à long terme de l'entreprise. Elle rejoint l'équipe de Voyager Therapeutics, où elle occupait le poste de Chief Business Officer. Auparavant, elle a occupé des postes de direction chez Takeda, Novartis et Roche.
Scholar Rock est une entreprise biopharmaceutique en phase avancée axée sur des traitements innovants pour l'atrophie musculaire spinale (SMA), les troubles cardiométaboliques et d'autres maladies où les facteurs de croissance protéiques jouent un rôle clé. Cette nomination intervient à un moment transformateur pour l'entreprise qui vise à construire une entreprise biopharmaceutique intégrée et à faire avancer son portefeuille de thérapies dans des domaines à forte valeur ajoutée.
Scholar Rock (NASDAQ: SRRK) hat Beth Shafer, Ph.D., zur Chief Business Officer ernannt, einer neu geschaffenen Position. Mit über 20 Jahren Erfahrung in der biopharmazeutischen Industrie wird Dr. Shafer die langfristige Geschäfts- und Unternehmensentwicklung des Unternehmens vorantreiben. Zuvor war sie Chief Business Officer bei Voyager Therapeutics. Davor hatte sie Führungspositionen bei Takeda, Novartis und Roche inne.
Scholar Rock ist ein biopharmazeutisches Unternehmen in der späten Phase, das sich auf innovative Behandlungen für spinale Muskelatrophie (SMA), kardiometabolische Erkrankungen und andere Krankheiten konzentriert, bei denen wachstumsfördernde Proteine eine Schlüsselrolle spielen. Die Ernennung erfolgt zu einem transformativen Zeitpunkt für das Unternehmen, das anstrebt, ein integriertes biopharmazeutisches Unternehmen aufzubauen und sein Therapienportfolio in wertvollen Bereichen voranzutreiben.
- Appointment of experienced executive Beth Shafer as Chief Business Officer
- Strengthening of leadership team to drive long-term corporate and business development strategy
- Focus on advancing pipeline in high-value therapeutic areas like cardiometabolic disorders
- None.
“We are pleased to welcome Beth to the executive team at a transformative time for Scholar Rock,” said Jay Backstrom, M.D., MPH, President and Chief Executive Officer of Scholar Rock. “Beth brings broad corporate strategy and business development experience which will be critical as we build an integrated biopharmaceutical company for the future and advance our pipeline of innovative therapies in high-value areas such as cardiometabolic disorders.”
“With a robust pipeline of highly differentiated growth factor-targeted therapeutics and multiple upcoming milestones across Scholar Rock’s portfolio, it is an exciting time to join Scholar Rock and help shape the company’s corporate strategy and execute development activities,” said Ms. Shafer. “I look forward to working with the team to maximize the reach of Scholar Rock’s potentially transformative therapies and deliver tremendous value to patients and their families.”
Ms. Shafer is a seasoned healthcare executive. She has led and built corporate and business development functions at several companies, and completed seminal transactions in key therapeutic areas, including neuroscience, gastroenterology, and ophthalmology. She joins Scholar Rock from Voyager Therapeutics, where she served as Chief Business Officer from 2023 to 2024. Prior to that, Ms. Shafer served as Vice President and Head of R&D Business Development at Takeda. Previously, she served as Head, Ophthalmology and Disease Area Business Development & Licensing at Novartis Institutes for Biomedical Research. She also served as Director, Business Development & Licensing at Roche.
Ms. Shafer has served as a member of the Board of Directors for Aquinnah Pharmaceuticals and Arcellx Inc. She currently serves as a Venture Partner to Mubadala Capital Ventures. She received her Ph.D. in Neuroscience from the University of
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role.
Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at ScholarRock.com and follow @ScholarRock and on LinkedIn.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information we post on our website, Twitter or LinkedIn could be deemed material information. As a result, we encourage investors, the media and others interested to review the information we post there regularly. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
Scholar Rock® is a registered trademark of Scholar Rock, Inc.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its growth, strategy, progress and development timing, the ability of any individual to affect the growth, strategy, and progress of Scholar Rock, and the potential of its product candidates and proprietary platform. The use of words such as “may,” “might,” “could,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials, and Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock’s Quarterly Report on Form 10-Q for the period ended June 30, 2024, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904163141/en/
Scholar Rock:
Investors & Media
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573
Molly MacLeod
Scholar Rock
mmacleod@scholarrock.com
media@scholarrock.com
802-579-5995
Source: Scholar Rock
FAQ
Who is the new Chief Business Officer of Scholar Rock (SRRK)?
What is Scholar Rock's (SRRK) main focus in drug development?
What is Beth Shafer's background before joining Scholar Rock (SRRK)?
Why did Scholar Rock (SRRK) create the Chief Business Officer role?
